Turn Biotechnologies

turn.bio

Aging has been called “the emperor of all maladies.” Turn Bio’s goal is to address multiple aging-related indications using a single powerful reprogramming therapy that turns old cells young again, aiding in the rejuvenation of an aged human body.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

news image

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More

Industrial Impact, Medical

CELULARITY AND CH TRADING GROUP DECLARES TERRITORY DISTRIBUTION AGREEMENT

Celularity | January 17, 2023

news image

Celularity Inc., a biotechnology firm based in the United States that develops placental-derived allogenic cell treatments and biomaterials, and CH Trading Group LLC, an international import, export, and trading corporation, have agreed to an exclusive territorial distribution agreement. CH Trading Group will serve as the exclusive territorial distributor for halal-certified products previously announced by Celularity in over 100 countries. The product distribution agreement for...

Read More

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

news image

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More

Cell and Gene Therapy, Medical

SYNTHEGO AND BIT.BIO EXPAND STRATEGIC PARTNERSHIP TO BUILD A PLATFORM FOR THE DEVELOPMENT OF SAFER AND MORE EFFICIENT GENETIC ENGINEERING OF HUMAN

prnewswire | August 25, 2023

news image

Synthego, a leading provider of industrialized genome editing solutions that accelerate discovery to clinic journey, and bit.bio, the company coding human cells for novel cures, today announced a strategic partnership to build a platform centered on the implementation of synthetic circuitry in cells for therapeutic application. bit.bio is building a pipeline of cell therapies focused on areas of unmet clinical need. The partnership will apply Synthego's expertise in gene edi...

Read More
news image

MINIPCR BIO ANNOUNCES LAUNCH OF THE GELATO™ AN INTEGRATED DNA ANALYSIS SYSTEM

miniPCR bio | September 09, 2020

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the GELATO™, an integrated DNA analysis system. GELATO™ combines gel electrophoresis with transillumination technology, allowing for simultaneous nucleic acid separation and visualization in a single, compact system. As a maker of innovative biotechnology for demanding settings, miniPCR bio has pioneered the development of tools that combine analytical power with the durabilit...

Read More
news image

Industrial Impact, Medical

CELULARITY AND CH TRADING GROUP DECLARES TERRITORY DISTRIBUTION AGREEMENT

Celularity | January 17, 2023

Celularity Inc., a biotechnology firm based in the United States that develops placental-derived allogenic cell treatments and biomaterials, and CH Trading Group LLC, an international import, export, and trading corporation, have agreed to an exclusive territorial distribution agreement. CH Trading Group will serve as the exclusive territorial distributor for halal-certified products previously announced by Celularity in over 100 countries. The product distribution agreement for...

Read More
news image

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More
news image

Cell and Gene Therapy, Medical

SYNTHEGO AND BIT.BIO EXPAND STRATEGIC PARTNERSHIP TO BUILD A PLATFORM FOR THE DEVELOPMENT OF SAFER AND MORE EFFICIENT GENETIC ENGINEERING OF HUMAN

prnewswire | August 25, 2023

Synthego, a leading provider of industrialized genome editing solutions that accelerate discovery to clinic journey, and bit.bio, the company coding human cells for novel cures, today announced a strategic partnership to build a platform centered on the implementation of synthetic circuitry in cells for therapeutic application. bit.bio is building a pipeline of cell therapies focused on areas of unmet clinical need. The partnership will apply Synthego's expertise in gene edi...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

Cell and Gene Therapy, Industrial Impact

GMP Grade PMSF and Protease Inhibitors

Whitepaper

resource image

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

Cell and Gene Therapy, Industrial Impact

GMP Grade PMSF and Protease Inhibitors

Whitepaper

resource image

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us